Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD34-positive cells · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Low Dose | ACTIVE_COMPARATOR | - |
| High Dose | ACTIVE_COMPARATOR | - |
| Saline | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CD34-positive cells | BIOLOGICAL | - |
| Saline and 5% autologous plasma | BIOLOGICAL | - |
Inclusion Criteria: * 21-80 years of age * moderate or high-risk Critical Limb Ischemia (Rutherford Clinical Severity Score 4 or 5) * unsuitable for conventional revascularization Exclusion Criteria: * advanced CLI (Rutherford Clinical Severity Score 6) characterized by extensive tissue loss or g...
CD34-positive cells are an investigational cell therapy being studied for the treatment of Peripheral Artery Disease, specifically critical limb ischemia, a severe form of peripheral vascular disease. The therapy involves injecting autologous CD34-positive cells into patients to potentially improve blood flow in affected limbs.
CD34-positive cells are a cell-based therapy, not a molecularly targeted drug. The treatment uses a patient's own CD34-positive stem cells, which are believed to promote angiogenesis and tissue repair in ischemic limbs affected by Peripheral Artery Disease. The exact mechanism of action is under investigation.
CD34-positive cells are being developed by Baxter International Inc., a company publicly traded under the ticker symbol BAX. The therapy is an autologous cell product, meaning it is derived from the patient's own cells and then reinjected to treat Peripheral Artery Disease.
CD34-positive cells are in Phase 1 clinical development for Peripheral Artery Disease. The therapy is investigational and has not been approved by regulatory authorities. A Phase 1 trial has been completed, but the product remains in early-stage clinical testing.
CD34-positive cells have been studied in one completed Phase 1 clinical trial, identified as NCT00616980, titled 'Injection of Autologous CD34-Positive Cells for Critical Limb Ischemia.' The trial enrolled 28 participants in the United States and was a randomized, double-blind, placebo-controlled study.
Yes, CD34-positive cells refer to the same therapy as autologous CD34-positive cells. The investigational treatment uses a patient's own CD34-positive cells, which are collected and reinjected to treat Peripheral Artery Disease. The clinical trial NCT00616980 specifically evaluated this autologous cell therapy.